JW Therapeutics Announces Exclusive Collaboration with 2seventy bio for Autoimmune Disease CAR-T Therapy
- Written by PR Newswire
SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, is pleased to announce an exclusive collaboration with 2seventy bio (NASDAQ: TSVT), for the co-development and commercialization of a...














